非小细胞肺癌免疫治疗进展

Progression in immunotherapy for non-small cell lung cancer

在过去十年中,非小细胞肺癌(non-small cell lung cancer, NSCLC)治疗经历了重大转变。对肺癌生物学机制更深入的了解促进了免疫治疗的发展,免疫检查点抑制剂(immunocheckpoint inhibitor, ICIs)在NSCLC的治疗中显示出巨大的益处,目前已成为晚期NSCLC患者不可或缺的治疗手段。同时,新型免疫治疗方案快速发展,因此,为了更好了解全世界范围内免疫治疗在NSCLC中的应用趋势,本文全面系统回顾了以免疫检查点抑制剂(ICIs)为代表的免疫治疗的临床研究进展,同时总结了新型免疫治疗疗法的应用进展,以期为免疫治疗NSCLC患者提供更多可借鉴应用成果。

Treatment of non-small cell lung cancer(NSCLC)has undergone a major transformation over the past decade.A deeper understanding of the biological mechanism of lung cancer has promoted the development of immunotherapy.Immunocheckpoint inhibitor(ICIs)has shown great benefits in the treatment of NSCLC and has become an indispensable treatment for patients with advanced NSCLC.At the same time,new immunotherapy regiments are developing rapidly.Therefore,in order to better understand the application trend of immunotherapy in NSCLC worldwide,this paper comprehensively and systematically reviews the clinical research progress of immunotherapy represented by immune checkpoint inhibitors(ICIs),and summarizes the application progress of new immunotherapy therapies.In order to provide more referential application results for immunotherapy patients with NSCLC.